1. Data & Insights

Optimizing Product Commercialization in Today’s IDN Environment

Written by Posted on Less than 0 min read

Today’s guest post comes from Greg Skalicky, President, EVERSANA; Krista Pinto, President, Deployment Solutions, EVERSANA; and Faruk Abdullah, President, Professional Services & Chief Business Officer, EVERSANA

Greg, Krista, and Faruk explain how and why integrated delivery networks (IDNs) have become crucial stakeholders for drug commercialization. They outline a two-pronged strategy to help brand teams thrive in today’s IDN landscape.

To learn more, read EVERSANA’s free report: IDN Trends and Engagement Strategies Every Drug Manufacturer Needs to Know.

Read on for Greg, Krista, and Faruk’s insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

Innovative Models for Improving Access and Visibility for Specialty-Lite and Retail Therapies

Today’s guest post comes from Timothy Nielsen, Vice President of Customer Success at AssistRx. Timothy discusses the affordability and patient journey challenges of specialty-lite products for patients, manufacturers, and health care providers. He explains how AssistRx’s Advanced Access Anywhere (AAA) solution streamlines processes for specialty-lite products and facilitates enrollment via a digital hub. To learn more, […]
2 min read
0
  1. Data & Insights

Patient Care’s Next Big Shift: 80% of Leaders Say This Is the Game Changer

Today’s guest post comes from Scott Genone, Chief Product Officer at CareMetx. Scott shares key findings from CareMetx’s recent survey of over 100 industry leaders. He explains how such advanced technologies as AI and machine learning will reshape patient services and improve the experience for both patients and healthcare providers. To view the full survey […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, September 2023: PBM Profits, Specialty Rx Markups, CVS Spending Trends, Pharmacy Pricing Secrets, and Deductibles 101

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the great Drug Channels patch: A must-read report on hidden sources of PBMs’ profits How generic drugs drive specialty pharmacy profits CVS Health’s unadvertised 2022 drug trend report A shocking look at how PBMs set prescription prices Plus, Dr. […]
2 min read
0
  1. Trends & External Forces

Medicare Part D in 2024: Smaller Pharmacies Abandon Preferred Pharmacy Networks

In a previous article, I highlighted the largest pharmacy chains that will participate in the 2024 Medicare Part D prescription drug plans (PDP). Today, I update DCI’s exclusive analysis of how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s Patient Assistance & Access Programs (PAP)

Informa Connect’s Patient Assistance & Access Programs (PAP) March 18-20, 2025 | Sheraton Philadelphia Downtown PA Pre-Conference Workshops on March 17, 2025 Drug Channels readers save 10% on their registration with code 25DC10 When it comes to patient affordability, it’s difficult to imagine a more complex time for our industry. Navigating policy updates, disarming AFPs, […]
3 min read
0
  1. Data & Insights

From Integration to AI: The Data-Driven Future of Market Access

Today’s guest post comes from Kala Bala, SVP, Enterprise Access & Data Expertise, MMIT, a Norstella company and Dinesh Kabaleeswaran, SVP, Advisory Services at MMIT, a Norstella company. The authors outline the challenges that manufacturers face when integrating internal and external datasets to build market access and commercialization strategies. They argue that unified datasets and […]
2 min read
0
  1. Channel: Drug

Can Rite Aid Recover?

Last fall, poor ol’ Rite Aid finally succumbed to bankruptcy. It was pretty much the definition of an expected surprise. To get a comprehensive look at the company’s ever-declining fortunes, DCI rummaged around the compnay’s numerous bankruptcy filings. Below, you’ll find our review of Rite Aid’s current financial situation, shrinking store footprint, changing relationship with […]
2 min read
0
  1. Media & Marketing

Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers

Today’s guest post comes from Hannah Baxter, Associate Partner at The Dedham Group; Jen Klarer, Partner, Head of Cell & Gene Therapy at The Dedham Group; and Carolyn Zele, Advisor, Solution Consulting at MMIT. The authors discuss the access barriers facing patients who need biomarker testing. They discuss five ways manufacturers can prevent these barriers […]
2 min read
0
  1. Trends & External Forces

EXCLUSIVE: The 340B Program Reached $54 Billion in 2022—Up 22% vs. 2021 (rerun)

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. My topic #9 for 2024: The Battle Over 340B Gets Even Messier. Click here to see the original post from September 2023. Drug Channels has just obtained new details on the size of the 340B Drug […]
3 min read
0
  1. Data & Insights

Shifting Strategies: Tackling Patient Support Program Reverification

Today’s guest post comes from Jan Nielsen, Patient Solutions Division President at AssistRx. Jan discusses the challenges facing life sciences organizations’ patient support program reverification processes. Jan then highlights how the right vendor can help overcome these challenges for both pharmacy and medical benefit products. She offers real-world examples how of AssistRx implements these solutions […]
2 min read
0
  1. Channel: Drug

Humira Biosimilar Price War Update: Should We Be Glad that CVS Health and Express Scripts Are Using Private Label Products to Pop the Gross-to-Net Bubble?

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Last week, Cigna’s Express Scripts announced that it that will follow CVS Health’s CVS Caremark business and remove Humira from its largest commercial formulary in favor of multiple biosimilars. Below, we review the 18 products competing with Humira—including four private-label […]
2 min read
0
  1. Trends & External Forces

Mark Cuban: Five Ways that Big PBMs Hurt U.S. Healthcare–And How We Can Fix It

Today’s guest post comes from Mark Cuban, co-founder of the Mark Cuban Cost Plus Drug Company A few weeks ago, Mark participated in the White House Roundtable on Lowering Healthcare Costs and Bringing Transparency to Prescription Drug Middlemen. I found Mark’s comments to be intriguing and highly provocative, so I invited him to publish an […]
2 min read
0
  1. Trends & External Forces

The Battle for Oncology Margin: How Private Equity Enables Vertical Integration by Pharmaceutical Wholesalers (rerun)

This week, I’m rerunning some popular posts while I prepare for tomorrow’s Drug Channels Outlook 2024 live video webinar. Click here to see the original post from October 2023. In case you haven’t noticed, private equity firms have displaced hospitals and health systems as the major acquirers of community oncology practices. These financial firms have […]
2 min read
0
  1. Trends & External Forces

PBM Power: The Gross-to-Net Bubble Reached $334 Billion in 2023—But Will Soon Start Deflating (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s Drug Channels Outlook 2025 live video webinar. Click here to see the original post. As you reread the article below, note that some manufacturers have already announced wholesale acquisition cost (WAC) list price declines for 2025. Last week, the Federal Trade Commission (FTC) […]
3 min read
0
  1. Department: Food

Drug Channels News Roundup, September 2024: Inside JNJ’s Gross-to-Net Bubble, Optum Rx’s Private Label Biosimilars, Where Biosimilars Boom, Accumulators vs. Patients, and Steve Collis Retires

Autumn is here! Curl up with your favorite pumpkin-spiced blog and savor these acorns that we’ve squirrelled away for you: Johnson & Johnson Innovative Medicines gives a peek inside its $43 billion gross-to-net bubble Optum Rx joins the private label biosimilar bandwagon Biosimilars boom for provider-administered drugs Fresh evidence of how copay accumulators hurt patients […]
2 min read
0
  1. Trends & External Forces

SAVE THE DATE: Drug Channels Leadership Forum, March 17-19, 2025

I am pleased to announce the inaugural Drug Channels Leadership Forum! This unique, new event will be held from March 17 to 19, 2025, at the Turnberry Resort and Spa in Miami. The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial […]
3 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2023: CVS’s New GPO, Medicaid vs. PBMs, 340B in Part D, and a Rockin’ Ex-CEO

Happy New Year, everyone! It has been another wild year for our ever-evolving healthcare system. Thank you, dear readers, for welcoming Drug Channels into your inboxes, browsers, and apps. I’m proud of the diverse and thoughtful audience who follows and comments on our unique content. The Drug Channels community now encompasses 50,000+ LinkedIn followers, 25,000+ […]
2 min read
0
  1. Technology & Innovation

Transforming Medication Access with the Next Generation of Patient Support Services

Today’s guest post comes from Kelly Martin, Vice President of Product Management at CoverMyMeds. Kelly discusses the obstacles that patients face when attempting to access, afford, and adhere to specialty therapies. She describes how CoverMyMeds improves the patient experience by blending technology with human expertise and connection. Click here to learn about CoverMyMed’s next-generation patient […]
2 min read
0
  1. Channel: Drug

The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. One important update to the figures below: We (and many others) had significantly underestimated Walgreens’ revenues and market share. As we discuss below, its market share is closer to 10%, compared […]
2 min read
0
  1. Data & Insights

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

This week, I’m rerunning some popular posts while I prepare for Fiday’s Drug Channels Outlook 2024 live video webinar. Click here to see the original post from September 2023. Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution […]
2 min read
0
Next